Skip to content Skip to footer
Subscribe Now
NEWS

Alvotech Reports the EMA’s Acceptance of MAA for AVT03 (Biosimilar, Prolia and Xgeva) 

Shots:  The EMA has accepted the marketing authorization application of AVT03, a biosimilar version of Prolia & Xgeva (denosumab)  Submission was based on the AVT03-GL-C01 trial among postmenopausal women (n=532) with osteoporosis as well as AVT03-GL-P01 (n=209) & AVT03-GL-P03 (n=208) studies among healthy adults, depicting similarity in efficacy, safety, immunogenicity & PK b/w the drugs …
October 10, 2024

Read more

NEWS

GlycoNex Reports the Completion of P-I Study Assessing SPD8 (Biosimilar, Prolia) for Osteoporosis 

  Shots:  GlycoNex, in partnership with Mitsubishi Gas Chemical Company, has concluded the P-I trial assessing SPD8, biosimilar version of Prolia (denosumab), for treating osteoporosis. Both the companies have completed the P-I study across Japan  Based on these results, SPD8 will proceed to P-III trial aimed at assessing its efficacy, safety & immunogenicity among larger…
August 19, 2024

Read more

NEWS

Alvotech and STADA Extend their Strategic Partnership Covering AVT03 (Biosimilar, Denosumab) 

Shots:  Alvotech & STADA expand their strategic collaboration covering AVT03, biosimilar of Prolia/Xgeva (denosumab), to treat osteoporosis & cancer-related bone loss, respectively  As per the agreement, AVT03 will be developed & manufactured by Alvotech at its state-of-the-art facility while STADA becomes marketing authorization holder with semi-exclusive commercial rights across the EU, incl. Switzerland & the…
June 11, 2024

Read more

Disease of the Month- Osteoporosis
INSIGHTS+

Disease of the Month- Osteoporosis

To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the disease of the month, PharmaShots brings a condensed report on Osteoporosis, a bone and tissue disorder  October 20th is observed as…
October 12, 2023

Read more

Laura Yecies, CEO at Bone Health Technologies Shares Insights on Osteoporosis Prevention Study for Postmenopausal Women With Osteopenia
VIEWPOINTS

Laura Yecies, CEO at Bone Health Technologies Shares Insights on Osteoporosis Prevention Study for Postmenopausal Women With Osteopenia

Shots: Laura spoke about the non-drug intervention study to treat osteopenia in postmenopausal women She also talked about the company’s OsteoBoost technology which is a convenient treatment to improve bone density The interview provides an understanding of the company’s vision to develop new treatment options for osteoporosis and osteopenia Smriti: Brief us about the background behind…
August 17, 2022

Read more